Neurocrine Biosciences Competitors and Similar CompaniesClear all
Neurocrine Biosciences's competitors and similar companies include Kalaris Therapeutics, Cipla, CSL Behring and UCB.
 Neurocrine Biosciences Neurocrine Biosciences is a biotechnology company focused on neurologic, psychiatric and endocrine-related disorders. |  Kalaris Therapeutics Kalaris Therapeutics (formerly known as AlloVir and ViraCyte) is a company that develops and delivers transformative cell therapies for patients suffering from life-threatening virus-associated diseases. |  Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products. |  UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. | ||
Founding Date | Founding Date 1992 | Founding Date 2013 | Founding Date 1935 | Founding Date 1904 | Founding Date 1928 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations San Diego, US HQ | Locations Waltham, US HQ Dublin, IE Milan, IT | Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more | Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more |
Employees | Employees 70020% increase | Employees 695% decrease | Employees 27,764 | Employees 7,5692% decrease | Employees 9,052 |
Valuation ($) | Valuation ($) 11.7 b | Valuation ($) 103.1 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 34.3 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $2.9b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) ₹277.1b (FY, 2026) | Revenue (est.) $7.9b (FY, 2020) | Revenue (est.) €7.4b (FY, 2025) |
Cost of goods | Cost of goods $52.1m (FY, 2025) | Cost of goods N/A | Cost of goods ₹95.5b (FY, 2026) | Cost of goods N/A | Cost of goods €1.4b (FY, 2025) |
Gross profit | Gross profit $2.8b (FY, 2025) | Gross profit N/A | Gross profit ₹195b (FY, 2026) | Gross profit $4.5b (FY, 2020) | Gross profit €7.2b (FY, 2025) |
Net income | Net income $478.6m (FY, 2025) | Net income ($43.4m) (FY, 2025) | Net income ₹38.7b (FY, 2026) | Net income N/A | Net income €1.6b (FY, 2025) |
Operating ⚠ | |||||
Countries | Countries N/A | Countries N/A | Countries N/A | Countries 100 (Dec, 2020) | Countries 35 (FY, 2019) |
Funding | |||||
Total funding raised | Total funding raised $ 10m | Total funding raised $ 159m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Kalaris Therapeutics
HQ
Waltham, US
Employees
6
Kalaris Therapeutics (formerly known as AlloVir and ViraCyte) is a company that develops and delivers transformative cell therapies for patients suffering from life-threatening virus-associated diseases.
View companyCipla
HQ
Mumbai, IN
Employees
27,764
Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
View companyUCB
HQ
Brussels, BE
Employees
9,052
UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
View company